{"result": "(\"entity\"<|>FDA<|>ORGANIZATION<|>The Food and Drug Administration (FDA) is a United States government agency responsible for regulating food, pharmaceuticals, and medical devices, including the approval of obesity treatments like lorcaserina.)\n##\n(\"entity\"<|>EMA<|>ORGANIZATION<|>The European Medicines Agency (EMA) is an agency of the European Union responsible for the evaluation and supervision of medicinal products, which rejected certain obesity treatments due to risk concerns.)\n##\n(\"entity\"<|>LORCASERINA<|>ORGANIZATION<|>Lorcaserina is a serotonin receptor agonist approved by the FDA for obesity treatment but rejected by the EMA due to safety concerns.)\n##\n(\"entity\"<|>FENTERMINE<|>ORGANIZATION<|>Fentermina is a medication used in combination with topiramate for obesity treatment, approved by the FDA but not by the EMA.)\n##\n(\"entity\"<|>TOPIRAMATO<|>ORGANIZATION<|>Topiramate is a medication used in combination with fentermina for the treatment of obesity, approved by the FDA but not by the EMA.)\n##\n(\"entity\"<|>BLOSSOM STUDY<|>EVENT<|>The BLOSSOM study is a clinical trial that evaluated the efficacy and tolerability of lorcaserina in treating obesity, involving over 4000 subjects.)\n##\n(\"entity\"<|>DINITROFENOL<|>ORGANIZATION<|>Dinitrofenol is a drug that was used for weight loss but was withdrawn due to severe side effects including neuropathy and cataracts.)\n##\n(\"entity\"<|>ANFETAMINAS<|>ORGANIZATION<|>Anfetaminas are stimulant drugs that were used for weight loss but were withdrawn due to risks of dependence and serious cardiovascular effects.)\n##\n(\"entity\"<|>AMINOREX<|>ORGANIZATION<|>Aminorex is a drug that was used for weight loss but was withdrawn due to the risk of pulmonary hypertension.)\n##\n(\"entity\"<|>MAZINDOL<|>ORGANIZATION<|>Mazindol is a weight loss medication that was suspended in Australia in 1993 due to safety concerns.)\n##\n(\"entity\"<|>FENFLURAMINA<|>ORGANIZATION<|>Fenfluramina is a weight loss drug that was withdrawn due to serious heart valve disease and pulmonary hypertension.)\n##\n(\"entity\"<|>DEXFENFLURAMINA<|>ORGANIZATION<|>Dexfenfluramina is a weight loss medication that was withdrawn due to serious heart valve disease and pulmonary hypertension.)\n##\n(\"entity\"<|>SIBUTRAMINA<|>ORGANIZATION<|>Sibutramina is a weight loss drug that was withdrawn due to cardiovascular risks.)\n##\n(\"entity\"<|>RIMONABANT<|>ORGANIZATION<|>Rimonabant is a weight loss medication that was withdrawn due to severe psychiatric side effects.)\n##\n(\"relationship\"<|>FDA<|>LORCASERINA<|>The FDA approved lorcaserina for obesity treatment in the United States<|>8)\n##\n(\"relationship\"<|>EMA<|>LORCASERINA<|>The EMA rejected lorcaserina for obesity treatment due to safety concerns<|>8)\n##\n(\"relationship\"<|>FDA<|>FENTERMINE<|>The FDA approved fentermina for obesity treatment in combination with topiramate<|>8)\n##\n(\"relationship\"<|>EMA<|>FENTERMINE<|>The EMA did not approve fentermina for obesity treatment<|>5)\n##\n(\"relationship\"<|>FDA<|>TOPIRAMATO<|>The FDA approved topiramato for obesity treatment in combination with fentermina<|>8)\n##\n(\"relationship\"<|>EMA<|>TOPIRAMATO<|>The EMA did not approve topiramato for obesity treatment<|>5)\n##\n(\"relationship\"<|>BLOSSOM STUDY<|>LORCASERINA<|>The BLOSSOM study evaluated the efficacy of lorcaserina in treating obesity<|>9)\n##\n(\"relationship\"<|>DINITROFENOL<|>FDA<|>Dinitrofenol was withdrawn from the market due to severe side effects, which the FDA regulates<|>6)\n##\n(\"relationship\"<|>ANFETAMINAS<|>FDA<|>Anfetaminas were withdrawn from the market due to serious health risks, which the FDA oversees<|>6)\n##\n(\"relationship\"<|>AMINOREX<|>FDA<|>Aminorex was withdrawn from the market due to health risks, which the FDA regulates<|>6)\n##\n(\"relationship\"<|>MAZINDOL<|>FDA<|>Mazindol was suspended due to safety concerns, which the FDA oversees<|>6)\n##\n(\"relationship\"<|>FENFLURAMINA<|>FDA<|>Fenfluramina was withdrawn due to serious health risks, which the FDA regulates<|>6)\n##\n(\"relationship\"<|>DEXFENFLURAMINA<|>FDA<|>Dexfenfluramina was withdrawn due to serious health risks, which the FDA regulates<|>6)\n##\n(\"relationship\"<|>SIBUTRAMINA<|>FDA<|>Sibutramina was withdrawn due to cardiovascular risks, which the FDA oversees<|>6)\n##\n(\"relationship\"<|>RIMONABANT<|>FDA<|>Rimonabant was withdrawn due to severe psychiatric side effects, which the FDA regulates<|>6)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: de las comorbilidades asociadas a la obesidad¹. Ese objetivo parece asumible y fácilmente factible a corto plazo para la mayoría de los pacientes motivados. Sin embargo, mantener el peso perdido constituye uno de los principales desafíos en una situación biológica y ambiental desfavorable, ya que la recuperación ponderal suele ser la norma para la mayoría de las personas que han intentado perder peso y mantenerlo a largo plazo².\n\nEn este escenario, disponer de un tratamiento farmacológico podría garantizar ese objetivo, si bien hasta ahora la aparición de efectos secundarios graves asociados a la toma de fármacos para el control del apetito y el peso corporal en el último siglo, ha motivado la retirada comercial sucesiva en estos años³, ⁴ (tabla 1). Por estos motivos, las agencias reguladoras se han mostrado muy cautas a la hora de aprobar nuevos fármacos para el tratamiento de la obesidad.\n\nEn la estrategia terapéutica para el tratamiento de la obesidad se contempla que, para que un fármaco sea considerado efectivo para tratar la obesidad, debe cumplir los siguientes requisitos: a) que alcance una diferencia de peso significativa respecto a un placebo > 5% al finalizar un año de tratamiento, y b) que el porcentaje de sujetos que pierdan más de un 5% de peso supere al 35% de los casos tratados activamente respecto al placebo (aproximadamente el doble de pacientes que en el grupo placebo). De la misma manera, las indicaciones del tratamiento farmacológico para la obesidad se establecen para los sujetos con un índice de masa corporal (IMC) ≥ 30 kg/m² o ≥ 27 kg/m² en presencia de comorbilidades mayores (diabetes, hipertensión, dislipemia, apneas del sueño, etc.)⁵, siempre asociadas a medidas dietéticas y cambios en el estilo de vida. De la misma manera, si tras 12-16 semanas de tratamiento activo el paciente no pierde al menos un 5% del peso inicial y/o aparecen efectos indeseables graves, se aconseja la retirada del tratamiento farmacológico.\n\n### 2. Fármacos comercializados no disponibles en Europa\n\nLa FDA (Food and Drug Administration) ha aprobado el empleo en Estados Unidos del tratamiento con lorcaserina y la combinación de fentermina y topiramato para el tratamiento de la obesidad. Sin embargo, han sido rechazados por la Agencia Europa del Medicamento (EMA) porque se consideró que los riesgos superaban a los beneficios esperados.\n\n#### 2.1. Lorcaserina (Belviq®)\n\nLorcaserina es un agonista del receptor de serotonina muy específico del subtipo 5HT2c implicado en la inhibición de la vía anorexígena a través de la estimulación que contienen neuronas con pro-opiomelanocortina (POMC). A diferencia de otros fármacos serotoninérgicos (dexfenfluramina, fenfluramina) lorcaserina no tendría supuestos efectos a nivel valvular o de hipertensión pulmonar (ligado a subtipos de receptor 5A o 5B), lo cual supone una gran ventaja teórica.\n---\n# BLOQUE: ALTERACIONES DE LA ENERGÍA\n\n## Tabla 1. Fármacos empleados para el tratamiento de la obesidad y razones para su retirada commercial\n\n| Fármaco | Año | Razones para la retirada (año) |\n|---------|-----|--------------------------------|\n| Dinitrofenol | 1930 | Riesgo de neuropatía y cataratas |\n| Anfetaminas | 1936 | Dependencia y abuso. Efectos cardiovasculares potencialmente graves. |\n| Aminorex | 1965 | Hipertensión pulmonar (1968) |\n| Mazindol | 1970 | Suspendida 1993 (Australia) |\n| Fenfluramina | 1963 Europa<br>1973 EEUU | Enfermedad valvular cardiaca Hipertensión pulmonar (1997) |\n| Dexfenfluramina | 1985 Europa<br>1996 EEUU | Enfermedad valvular cardiaca Hipertensión pulmonar (1997) |\n| Sibutramina | 1997 EEUU<br>2001 Europa | Enfermedad cardiovascular (2010) |\n| Rimonabant | 2006 Europa | Alteraciones psiquiátricas graves (2009) |\n\nLa tolerabilidad y eficacia de lorcaserina han sido evaluadas en tres ensayos clínicos aleatorizados doble ciego frente a placebo. El Estudio BLOSSOM (Behavioral Modification and Lorcaserin Second Study for Obesity Management)6 incluyó 4008 sujetos con obesidad o sobrepeso a recibir lorcaserina 10 mg/día (n = 801), 10 mg/2 veces al día (n = 1602) o placebo (n = 1601) durante 52 semanas. La tasa de pérdidas\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}